Related Experiment Video
Updated: May 26, 2026
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening
Rodger E Tiedemann1, Yuan Xao Zhu, Jessica Schmidt
1Princess Margaret Hospital, Ontario Cancer Institute and the University of Toronto, Toronto, Ontario, Canada. rodger.tiedemann@uhnresearch.ca
Abstract:
Despite recent advances in targeted treatments for multiple myeloma, optimal molecular therapeutic targets have yet to be identified. To functionally identify critical molecular targets, we conducted a genome-scale lethality study in multiple myeloma cells using siRNAs. We validated the top 160 lethal hits with four siRNAs per gene in three multiple myeloma cell lines and two non-myeloma cell lines, cataloging a total of 57 potent multiple myeloma survival genes. We identified the Bcl2 family member MCL1 and several 26S proteasome subunits among the most important and selective multiple myeloma survival genes. These results provided biologic validation of our screening strategy. Other essential targets included genes involved in RNA splicing, ubiquitination, transcription, translation, and mitosis. Several of the multiple myeloma survival genes, especially MCL1, TNK2, CDK11, and WBSCR22, exhibited differential expression in primary plasma cells compared with other human primary somatic tissues. Overall, the most striking differential functional vulnerabilities between multiple myeloma and non-multiple myeloma cells were found to occur within the 20S proteasome subunits, MCL1, RRM1, USP8, and CKAP5. We propose that these genes should be investigated further as potential therapeutic targets in multiple myeloma.
Insights
Researchers identified key survival genes in multiple myeloma using a genome-wide screen. MCL1 and proteasome subunits are critical targets for new multiple myeloma therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapies for multiple myeloma are advancing, but optimal molecular targets remain elusive.
- Identifying novel therapeutic targets is crucial for improving patient outcomes.
Purpose of the Study:
- To functionally identify critical molecular targets in multiple myeloma cells.
- To discover genes essential for multiple myeloma cell survival through a genome-scale screen.
Main Methods:
- Conducted a genome-scale lethality study using small interfering RNAs (siRNAs) in multiple myeloma cells.
- Validated top lethal hits across multiple myeloma and non-myeloma cell lines.
- Cataloged potent multiple myeloma survival genes.
Main Results:
- Identified 57 potent multiple myeloma survival genes, including MCL1 and 26S proteasome subunits.
- Validated MCL1 and proteasome subunits as highly selective and important survival genes.
- Discovered differential functional vulnerabilities in 20S proteasome subunits, MCL1, RRM1, USP8, and CKAP5 between multiple myeloma and non-myeloma cells.
Conclusions:
- The screening strategy was biologically validated.
- Identified novel therapeutic targets including MCL1, TNK2, CDK11, and WBSCR22.
- Propose further investigation of identified genes, particularly proteasome subunits and MCL1, as potential multiple myeloma therapeutic targets.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
